ES2172195T3 - Inhibicion de la cristalizacion en dispositivos transdermales. - Google Patents

Inhibicion de la cristalizacion en dispositivos transdermales.

Info

Publication number
ES2172195T3
ES2172195T3 ES98944097T ES98944097T ES2172195T3 ES 2172195 T3 ES2172195 T3 ES 2172195T3 ES 98944097 T ES98944097 T ES 98944097T ES 98944097 T ES98944097 T ES 98944097T ES 2172195 T3 ES2172195 T3 ES 2172195T3
Authority
ES
Spain
Prior art keywords
drug component
active drug
active
matrix
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98944097T
Other languages
English (en)
Inventor
Fabian Isaac Biali
Alejandro Fabio Scasso
Francisco Jose Evarist Stefano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amarin Technologies SA
Original Assignee
Amarin Technologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Technologies SA filed Critical Amarin Technologies SA
Application granted granted Critical
Publication of ES2172195T3 publication Critical patent/ES2172195T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Procedimiento de preparación de un dispositivo de administración transdermal que incluye las etapas de preparación de la mezcla de un componente de fármaco activo en cantidad suficiente para tener un efecto farmacéutico o fisiológico en la utilización del dispositivo y un material que forma la matriz, y disponiendo dicha mezcla en o sobre un soporte para formar una matriz que contenga dicho componente de fármaco activo, siendo dicho componente de fármaco activo una fármaco de hormona activo o un conjunto de fármacos de hormonas activas, estando el procedimiento caracterizado por el paso de mezclar de al menos uno de los mencionados materiales que constituyen la matriz y dicho componente de fármaco activo con una cantidad medida de un esteroide, teniendo dicha cantidad medida un efecto de inhibición de la cristalización de dicho componente de fármaco activo al almacenar el dispositivo terminado y estando en una cantidad insuficiente para provocar un efecto farmacéutico o siológico significativo cuando se utiliza el dispositivo.
ES98944097T 1997-09-25 1998-09-24 Inhibicion de la cristalizacion en dispositivos transdermales. Expired - Lifetime ES2172195T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9720470.5A GB9720470D0 (en) 1997-09-25 1997-09-25 Inhibition of crystallization in transdermal devices

Publications (1)

Publication Number Publication Date
ES2172195T3 true ES2172195T3 (es) 2002-09-16

Family

ID=10819670

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98944097T Expired - Lifetime ES2172195T3 (es) 1997-09-25 1998-09-24 Inhibicion de la cristalizacion en dispositivos transdermales.

Country Status (8)

Country Link
US (1) US6465005B1 (es)
EP (1) EP1023055B1 (es)
AR (1) AR013520A1 (es)
BR (1) BR9812523A (es)
DE (1) DE69803592T2 (es)
ES (1) ES2172195T3 (es)
GB (1) GB9720470D0 (es)
WO (1) WO1999015156A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074661A2 (en) 1999-06-05 2000-12-14 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
ATE355854T1 (de) * 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
AU2002235155A1 (en) * 2000-12-05 2002-06-18 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
PT1406633E (pt) 2001-06-18 2012-01-12 Noven Pharma Distribuição melhorada de fármacos em sistemas transdérmicos
US20050058695A1 (en) * 2002-05-30 2005-03-17 Watson Pharmaccuticals, Inc. Norethindrone sustained release formulations and methods associated therewith
CN1655794A (zh) * 2002-05-30 2005-08-17 沃特森药物公司 炔诺酮持续释放制剂及其有关方法
EP1670433B1 (en) * 2003-10-10 2011-11-23 Antares Pharma IPL AG Transdermal pharmaceutical formulation for minimizing skin residues
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
TW200514582A (en) * 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
US10137135B2 (en) * 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
FR2895679B1 (fr) * 2005-12-29 2012-06-08 Pf Medicament Stabilisation de testosterone au sein de dispositifs transdermiques
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
US20100086582A1 (en) * 2008-10-06 2010-04-08 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
KR20140088199A (ko) 2011-11-04 2014-07-09 애자일 쎄라퓨틱스, 인크. 경피 전달 조성물 및 방법
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4832953A (en) 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US4906475A (en) 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
AU630347B2 (en) 1988-02-26 1992-10-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US4814168A (en) 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
WO1990006120A1 (en) 1988-12-01 1990-06-14 Schering Corporation Compositions for transdermal delivery of estradiol
AR246186A1 (es) 1989-11-17 1994-07-29 Beta Pharm Co Procedimiento para fabricar un dispositivo para administrar estradiol por via transdermica.
GB9021674D0 (en) 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5518734A (en) 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
DE4210711A1 (de) * 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
DE4429664C2 (de) 1994-08-20 1997-09-11 Lohmann Therapie Syst Lts Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same

Also Published As

Publication number Publication date
US6465005B1 (en) 2002-10-15
GB9720470D0 (en) 1997-11-26
AR013520A1 (es) 2000-12-27
DE69803592D1 (de) 2002-03-14
EP1023055A1 (en) 2000-08-02
EP1023055B1 (en) 2002-01-23
WO1999015156B1 (en) 1999-06-10
BR9812523A (pt) 2000-07-25
DE69803592T2 (de) 2002-09-19
WO1999015156A1 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
ES2172195T3 (es) Inhibicion de la cristalizacion en dispositivos transdermales.
AU741482B2 (en) Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
CN101282701B (zh) 提供单纯孕激素避孕并将与之关联的不良副作用减到最小的制剂和方法
FI960556A (fi) Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärjestelmä
ES2045153T3 (es) Metodo para la preparacion de formas de dosificacion de farmacos con liberacion sostenida que contienen hidroxi-propil-metilcelulosa y carboxilatos de metales alcalinos.
RU2700926C2 (ru) Трансдермальные системы, предотвращающие злоупотребление и неправильное употребление
WO2001052823A3 (en) Compositions to effect the release profile in the transdermal administration of drugs
AR064078A1 (es) Sistema de administracion de farmacos intraocular inyectable biocompatible, su uso para preparar un medicamento y proceso para su preparacion
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
AU7465087A (en) Controlled release bioerodible drug delivery system
BRPI0518460A2 (pt) mÉtodo para tratar emergÊncia alÉrgica em um paciente, dispositivo de distribuiÇço de droga contendo uma soluÇço de epinefrina, e, kit para tratar uma emergÊncia alÉrgia'
CN101511349A (zh) 包含甲基孕酮的透皮治疗系统用于避孕和激素替代疗法
CY1117127T1 (el) Συσκευη απονομης φαρμακευτικου υλικου
PT87936B (pt) Sistema de tratamento transdermico e sua utilizacao
CZ307857B6 (cs) Transdermální náplast pro podávání fentanylu nebo jeho analogu
DE69212497D1 (de) Glasartige kohlenhydratenmatrize zur verabreichung von heilmitteln mit verzögerter wirkstoffabgabe
AR076718A1 (es) Modulo medicinal con seleccion del usuario
ES2158886T3 (es) Jeringuilla.
AU2020200951B2 (en) Once-a-day replacement transdermal administration of fentanyl
KR101307650B1 (ko) 구역에 대한 경피 방법 및 패치
Mofidfar et al. Pharmaceutical jewelry: Earring patch for transdermal delivery of contraceptive hormone
BRPI0414471A (pt) nova formulação farmacêutica contendo biguanida e um derivado de tiazolidinadiona
CO5601036A2 (es) Composicion farmaceutica de liberacion sostenida
AR044939A1 (es) Sistema de administracion para medicaciones topicas
ES2188513T3 (es) Utilizacion de desoxipeganina para el tratamiento de la drogodependencia.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1023055

Country of ref document: ES